The FDA may sniff Galliprant is just another NSAID but the drug is doing for our youngish border collie mix with severe osteoarthritis what a higher-priced wonder drug didn't and couldn't with limitations on its use. Dixie's arthritis was so bad I had expected to hear she had osteosarcoma [a bone cancer that Sam is all too familiar with I assume but in dogs osteoarthritis is a killer too].
Eli Lilly handed PETX a contract to bring Galliprant to FDA approval for its billion-dollar veterinary subsidiary and as a stalking horse* for its human prostaglandin drug that Eli Lilly intends to do some terrible hurt to all those surgeons doing knee and hip replacements.
Maybe, Sam, you know of such glorious plans for other NSAIDS but I do not.
I assume others here know PETX is also attempting to get conditional approval for an anti-bone cancer vaccine but from the Agriculture Department rather than the FDA. My suspicion is the FDA would already have given full approval but how do you tell ag people about treatment vaccines as opposed to prophylactic vaccines.
I expect even the conditional approval will be helpful to PETX's PPS though not so kind to its balance sheet.
Admittedly I may be over-optimistic when it comes to dogs and those who help them.
Best, Terry
* I have a peculiar fascination with politicians being falsely charged with being extinct stalking horses. Fishermen once hid behind such horses because the fish saw no threat from horses but did from humans. I love to use the term correctly even if it's a stretch.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
